Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma

SIMPLE SUMMARY: The combination of atezolizumab and bevacizumab was introduced as a first-line therapy for patients with unresectable hepatocellular carcinoma in 2020. Although some patients have shown a treatment response, there have also been those with disease progression. Such cases should be ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanabe, Norikazu, Saeki, Issei, Aibe, Yuki, Matsuda, Takashi, Hanazono, Tadasuke, Nishi, Maiko, Hidaka, Isao, Kuwashiro, Shinya, Shiratsuki, Shogo, Matsuura, Keiji, Egusa, Maho, Nishiyama, Natsuko, Fujioka, Tsuyoshi, Kawamoto, Daiki, Sasaki, Ryo, Nishimura, Tatsuro, Oono, Takashi, Hisanaga, Takuro, Matsumoto, Toshihiko, Ishikawa, Tsuyoshi, Yamasaki, Takahiro, Takami, Taro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251947/
https://www.ncbi.nlm.nih.gov/pubmed/37296889
http://dx.doi.org/10.3390/cancers15112927

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251947/
https://www.ncbi.nlm.nih.gov/pubmed/37296889
http://dx.doi.org/10.3390/cancers15112927

Ejemplares similares